Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome

Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome

Apixaban, an oral, direct factor Xa inhibitor, may reduce the risk of recurrent ischemic events when added to antiplatelet therapy after an acute coronary syndrome.

Furkejuvvon:

Bibliográfalaš dieđut
Váldodahkkit:	John H. Alexander, Renato D. Lópes, Stefan James, Rakhi Kilaru, Yaohua He, Puneet Mohan, Deepak L. Bhatt, Shaun G. Goodman, Freek W.A. Verheugt, Marcus Flather, Kurt Huber, Danny Liaw, Steen Husted, José López‐Sendón, Raffaele De Caterina, Petr Janský, Harald Darius, Dragoş Vinereanu, Jan H. Cornel, Frank Cools, Dan Atar, José L. Leiva-Pons, Matyàs Keltai, Hisao Ogawa, Prem Pais, Alexander Parkhomenko, Witold Rużyłło, Rafael Díaz, Harvey D. White, Mikhail Ruda, Margarida Geraldes, Jack Lawrence, Robert A. Harrington, Lars Wallentin
Materiálatiipa:	Artigo
Giella:	eaŋgalasgiella
Almmustuhtton:	2011
Liŋkkat:	https://doi.org/10.1056/nejmoa1105819 https://www.nejm.org/doi/pdf/10.1056/NEJMoa1105819?articleTools=true
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!

Interneahtta

https://doi.org/10.1056/nejmoa1105819
https://www.nejm.org/doi/pdf/10.1056/NEJMoa1105819?articleTools=true